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Resveratrol is a polyphenol with major health benefits1 that is thought to operate 
through direct activation of the ‘anti-aging’ enzyme SIRT12. However recent reports 
have challenged this ‘direct-activation’ hypothesis3-4, suggesting the mechanism by 
which resveratrol increases SIRT1 function is still unknown.  We report for the first 
time that resveratrol induces a dose dependent increase in activity of the NAD+
synthetic enzyme nicotinamide mononucleotide adenylyl transferase (NMNAT1). 
Activation of NMNAT1 by resveratrol in cultured primary human astrocytes and 
neurons increased NAD+ levels by up to 5 fold.  As SIRT1 requires NAD+ as a substrate 
to perform its gene silencing function5, higher NAD+ levels will enhance SIRT1 activity6.
This finding suggests that resveratrol may promote SIRT1 function by enhancing NAD+
synthesis in whole cell systems without requiring direct activation. 
Resveratrol is a non-vitamin antioxidant common in the diet and particularly abundant in 
teas, juices, and red wines that is thought to harbour major health benefits1. Experiments in 
single and multicellular organisms and human tissue cultures suggest that resveratrol can 
extend the lifespan in diverse organisms by activating the NAD+ dependent, enzyme, SIRT17.
The neuroprotective ability of SIRT1 induced by resveratrol has been demonstrated in vitro6.
While resveratrol has been claimed to be a direct SIRT1 activator using the Fluor de Lys-
SIRT1 peptide substrate, recent reports indicate that this finding may represent an 
experimental artefact3-4. Our study indicates resveratrol directly activates the enzyme 
NMNAT1 which likely influences downstream SIRT1 activity.
 We demonstrate for the first time that resveratrol significantly increases intracellular 
NAD+ levels in primary human astrocytes and neurons (Fig 1). We have shown that 
resveratrol can induce a dose dependent increase in NAD+ of 3-5 fold in human astrocytes 
(Fig 1A) and neurons (Fig 1B) after 24-hour treatment. It has been known for some time that 
resveratrol can influence NAD+ responsive enzymes, such as the energy-sensing AMP-
activated kinase (AMPK)8 and SIRT22 and its mammalian homologue, SIRT12, 9. However to 
date no study has reported a link between resveratrol and changes in NAD+ concentration. 
Elevated cellular levels of NAD+, the required substrate for SIRT1, will increase its activity. 
 Nicotinamide mononucleotide adenylyltransferase (NMNAT) is an NAD+ synthetic 
enzyme which catalyses the conversion of nicotinamide mononucleotide (NMN) to NAD+.
NMNAT1 is the predominant human isoform of NMNAT and is located in the nucleus6.
Increased NMNAT1 expression has been reported to protect against axonal degradation via 
increased NAD+ production in mouse neurons6. In the same study, neurons treated with 
resveratrol prior to axotomy showed a decrease in axonal degeneration that was comparable 
to that obtained with NAD+ 6. It has also been previously demonstrated that increased SIRT1 
deacetylase activity can protect against axonal degradation in models of AD, although the 
exact mechanism is still unknown10. As NAD+ is an essential substrate for SIRT1, the effect 
of resveratrol on SIRT1 proteins may be due, at least in part, to an NMNAT mediated 
increase in NAD+.
We tested the effect of resveratrol on NMNAT activity in cell homogenates of human foetal 
astrocytes and human recombinant-NMNAT1. We found that resveratrol (200 µM) increased 
NMNAT1 activity in crude astrocytic homogenates by 70% within 24 hours (Fig 1C). Using 
human recombinant NMNAT1, we observed that resveratrol lowered the Km for the substrate 
NMN by up to 3-fold, and increased Vmax for the recombinant NMNAT1 by up to 5 fold in a 
dose dependent manner (Table 1). Our results are consistent with resveratrol acting as a 
heterotropic allosteric modulator of NMNAT1 at an as yet unidentified site. Further work is 
required to characterise this novel resveratrol-NMNAT1 interaction. 
Our observation that resveratrol increases NAD+ levels in primary human brain cells by 
acting on NMNAT supports the view that this polyphenol has considerable therapeutic 
potential;  particularly for the treatment of neurodegenerative diseases. As NMNAT can 
accelerate NAD+ synthesis from all three substrates, quinolinic acid, nicotinic acid and 
nicotinamide11, NMNAT activation by resveratrol represents an ideal natural therapeutic to 
replenish NAD+ levels. Maintenance of higher cellular NAD+ will enhance SIRT1 activity, 
and other NAD+ dependent pathways impacting positively on cell viability and longevity. 
This work has therefore formed the basis of relevant patent applications.
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FIGURE LEGENDS 

Figure 1. Resveratrol increases intracellular NAD+ levels in (a) human foetal astrocytes 
and (b) human foetal neurons, after 24-hour treatment. (c) Effect of resveratrol (200 
µM) on NMNAT-1 activity in astrocytic nuclear homogenates. P<0.05 compared to 
control, (n=4 at each drug concentration) 
Table 1. Resveratrol increases human recombinant NMNAT1 activity
(A separate kinetic experiment was carried out for each substrate and resveratrol 
concentration)

Figure 1 (Grant)
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